ArticleIDCases2025
Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK Polyomavirus (BKPyV) is an important risk factor for premature graft loss following kidney transplant. Current practice guidelines recommend screening for BK virus DNA for 2 years after kidney transplant as the risk of BK Polyomavirus associated nephropathy (BKPyVAN) wanes over time. This case report presents a unique scenario of late onset BKPyVAN 15 years following kidney transplant precipitated by administration of chemotherapy to treat multiple myeloma. A woman in her 60 s with no prior history of BKPyV was diagnosed with multiple myeloma 14 years after kidney transplant. Her immunosuppression was tapered to tacrolimus and prednisone before undergoing chemotherapy treatment for her multiple myeloma. Although the chemotherapy was effective in achieving remission of her myeloma, she developed worsening renal dysfunction without proteinuria. Kidney biopsy revealed positive SV40 staining and subsequent BK DNA serum PCR was found to be 236,000 copies/mL suggestive of BKPyVAN. Although incredibly rare, late onset BKPyVAN should be considered as a cause of sustained elevation in serum creatinine, new onset proteinuria, or new onset hematuria in kidney transplant recipients who have experienced an augmentation in immunosuppression such as patients undergoing chemotherapy for underlying malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.